Lynparza +/- bevacizumab demonstrates clinically meaningful survival benefit in 1L advanced ovarian cancer across PAOLA-1 and SOLO-1 Ph 3 trials September 13, 2022
Patient-Reported Outcomes with Mirvetuximab vs Chemo in FORWARD I Study Reinforces Differentiated Tolerability Profile September 13, 2022
Rubraca® (Rucaparib) As 1L Maintenance Treatment Improves PFS In Women With Advanced Ovarian Cancer Across Disease Risk Subgroups September 13, 2022
SELLAS Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian Cancer June 14, 2022
Modi-1 Ph 1/2 trial open for recruitment in patients with TNBC, ovarian cancer, head and neck cancer, and RCC April 12, 2022
Incyclix Bio Announces $30M Series B Financing to Support Clinical Development of INX-315 April 1, 2022
